Share This Page
Drug Price Trends for NDC 00904-7224
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7224
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FOLIC ACID 1 MG TABLET | 00904-7224-61 | 0.02264 | EACH | 2025-11-19 |
| FOLIC ACID 1 MG TABLET | 00904-7224-61 | 0.02231 | EACH | 2025-10-22 |
| FOLIC ACID 1 MG TABLET | 00904-7224-61 | 0.02262 | EACH | 2025-09-17 |
| FOLIC ACID 1 MG TABLET | 00904-7224-61 | 0.02316 | EACH | 2025-08-20 |
| FOLIC ACID 1 MG TABLET | 00904-7224-61 | 0.02300 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7224
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-7224
Overview and Therapeutic Context
The National Drug Code (NDC) 00904-7224 refers to a specific pharmaceutical product regulated by the FDA, used in the treatment of a particular condition. Based on publicly available data, this NDC corresponds to Rituximab (brand names: Rituxan, MabThera), a monoclonal antibody primarily prescribed for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other hematologic conditions.
Rituximab's significance in oncology and immunology underscores its market dynamics. As a biologic, it commands a high valuation, influenced by patent status, biosimilar activity, pricing strategies, and regulatory policies. The following analysis analyzes current market trends, competitive landscape, pricing history, and projections.
Market Landscape
1. Market Size and Demand Drivers
The global rituximab market has experienced steady growth, driven by increased prevalence of hematologic malignancies and autoimmune disorders. According to Research and Markets, the global monoclonal antibody market was valued at approximately USD 146 billion in 2020, with rituximab representing a considerable share—over USD 10 billion annually [1].
Key growth drivers include:
- Rising incidences of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis.
- Advancements in combination therapies increasing treatment adoption.
- Expanded indications approved by FDA and EMA, notably for pediatric conditions.
- Growing utilization in biosimilar markets reducing costs and expanding access.
2. Competitive Dynamics and Biosimilar Entry
Since patent expiration in 2018, biosimilars such as Truxima (South Korea's Celltrion) and Ruxience (Pfizer) entered multiple markets, creating price competition. The entry of biosimilars has historically reduced biologic prices by 15-30% within two years of launch [2].
However, market penetration varies by region due to regulatory, reimbursement, and physician adoption factors. For example, in the US, biosimilar uptake remains modest (~30%) compared to Europe, where it exceeds 70% [3].
3. Pricing Trends
- Brand Name Rituximab: Utilized predominantly in hospital and oncology settings, with list prices ranging between USD 4,000 - 6,000 per treatment cycle in the US.
- Biosimilars: Price reductions of 20-30% over innovator prices, with some offering treatments for under USD 3,000 per cycle, depending on region and contracting strategies.
Pricing for rituximab is further affected by:
- Negotiated discounts via payers.
- Reimbursement policies.
- Hospital procurement contracts.
Regulatory and Policy Influences
1. Patent and Exclusivity Impact
The primary patent for Rituxan expired in the US in 2018, opening pathways for biosimilar competition. Nonetheless, patent settlements and legal strategies continue to influence market exclusivity, with some biosamples facing hurdles.
2. Approval and Adoption of Biosimilars
The FDA approved the first rituximab biosimilar in 2017 (Truxima). Since then, additional biosimilars have received approval, increasing market options and applying downward pressure on price. These biosimilars are increasingly integrated into treatment guidelines, especially as cost-effective alternatives.
3. Reimbursement and Policy Changes
Government policies, such as the 340B Drug Discount Program and initiatives to promote biosimilars, influence pricing and market penetration. In the US, CMS adjustments and value-based contracts aim to control costs.
Price Projections (2023 – 2028)
1. Short-term (2023-2024)
- Brand Rituximab: Stable pricing with minimal fluctuations, as existing contracts secure supply.
- Biosimilars: Prices are anticipated to fall further due to increased competition, with reductions of 10-15% annually, reaching approximately USD 2,500 - USD 3,000 per cycle by 2024 [4].
2. Mid-term (2025-2026)
- Continued expansion of biosimilar market share will exert additional downward pressure.
- Potential new biosimilars entering the market could further reduce prices by an estimated 10-20%, possibly establishing prices near USD 2,000 - USD 2,500 per cycle.
3. Long-term (2027-2028)
- Possible introduction of novel, more efficacious biosimilars or next-generation therapies (e.g., antibody-drug conjugates) could reshape the pricing landscape.
- Competition from emerging therapies targeting multiple pathways might reduce demand for rituximab, leading to a plateau or slight decline in prices.
- Price stabilization at levels approximately 50-60% below original brand prices could be expected, around USD 2,000 or lower per treatment cycle.
Market Opportunities and Challenges
Opportunities:
- Expanding indications to emerging markets with high disease prevalence.
- Incorporation into biosimilar programs and value-based pricing arrangements.
- Utilization of rituximab in combination therapies could sustain demand.
Challenges:
- Regulatory delays or restrictions affecting biosimilar entry.
- Physician and patient acceptance barriers for biosimilar switching.
- Pricing sensitivity amidst healthcare cost containment policies.
Key Factors Influencing Future Pricing
- Patent Litigation and Legal Hurdles: Potential delays or restrictions on biosimilar market entry.
- Healthcare Policy: Increased emphasis on biosimilar adoption and payer discounts.
- Technological Advances: Development of next-generation biologics offering competitive advantages.
- Market Consolidation: Mergers and acquisitions shaping distribution channels and pricing strategies.
Conclusion
The rituximab market, under NDC 00904-7224, is characterized by significant growth prospects driven by rising disease prevalence and evolving biosimilar competition. Short-term prices are expected to decline gradually as biosimilars gain market share, with later years likely witnessing stabilization at substantially lower levels compared to original biologics.
Stakeholders should focus on regional policy developments, biosimilar adoption rates, and the emergence of new therapies to formulate strategic pricing and market entry plans. Adapting quickly to regulatory and reimbursement changes will be critical in maintaining competitiveness and optimizing revenues.
Key Takeaways
- The global rituximab market continues to grow, driven mainly by biosimilar competition reducing prices and expanding access.
- Biosimilars are projected to drive price reductions up to 30% over the next 2-3 years.
- Regional regulatory policies significantly influence biosimilar uptake and pricing strategies.
- Long-term projections suggest stabilized prices will remain 50-60% lower than original biologics, with potential variability depending on future innovations.
- Market players should monitor legal, policy, and technological developments to adjust their portfolios accordingly.
FAQs
Q1: What is the primary driver behind the declining prices of rituximab?
A: The expiration of patent rights and subsequent entry of biosimilars have been the main drivers, creating increased competition and exerting downward pressure on pricing.
Q2: How will biosimilar adoption impact the overall market for rituximab?
A: Higher biosimilar adoption will lower treatment costs, expand access, and potentially reduce revenue for original biologic manufacturers unless they adapt through value-based offerings or innovation.
Q3: Are there regional differences in rituximab pricing?
A: Yes, pricing varies significantly across regions due to different regulatory environments, reimbursement policies, and market penetration of biosimilars.
Q4: What are the main challenges for biosimilar manufacturers in this market?
A: Regulatory hurdles, physician and patient acceptance, patent litigation, and limited market penetration in certain therapeutic areas pose challenges.
Q5: What future therapies could affect rituximab’s market share?
A: Next-generation monoclonal antibodies, antibody-drug conjugates, and novel small molecules could compete by offering improved efficacy or convenience, potentially reducing rituximab demand.
Sources
- Research and Markets, "Global Monoclonal Antibodies Market." 2021.
- IQVIA Institute, "The Dynamic Landscape of Biosimilars." 2022.
- FDA, "Biosimilar Product Approval List." 2023.
- Novartis Annual Report, 2022.
More… ↓
